(RTTNews) - The U.S. Food and Drug Administration Friday said it has approved Genzyme Corporation's Nexviazyme for treatment of patients 1 year of age and older with late-onset Pompe disease ...

The Food and Drug Administration has approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease Paris, February ...

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease Approval is based on positive Phase 3 data demonstrating improvements in key ...

This week, the FDA approved Sanofi’s SNY late-onset Pompe disease drug, Nexviazyme (avalglucosidase alfa) and Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda plus Lenvima for expanded use in ...